Advertisement
Research Article Free access | 10.1172/JCI109443
Find articles by Gordon, L. in: JCI | PubMed | Google Scholar
Find articles by Douglas, S. in: JCI | PubMed | Google Scholar
Find articles by Kay, N. in: JCI | PubMed | Google Scholar
Find articles by Yamada, O. in: JCI | PubMed | Google Scholar
Find articles by Osserman, E. in: JCI | PubMed | Google Scholar
Find articles by Jacob, H. in: JCI | PubMed | Google Scholar
Published July 1, 1979 - More info
Host responses to infectious organisms should be modulated so that tissue-damaging products of inflammatory cells do not produce excessive destruction of normal tissue. Lysozyme, which is continuously secreted by monocytes, which, in turn, migrate relatively late to inflammatory areas, was found to significantly dampen several responses of neutrophils to inflammatory stimulants. Thus, human lysozyme obtained and purified from the urine of patients with monocytic leukemia (but not its structurally similar and comparably cationic analogue, eggwhite lysozyme) depresses chemotaxis of normal neutrophils to activated complement, bacterial supernate, and N-formylmethionyl-phenylalanine. In addition, human (but not eggwhite) lysozyme depresses oxidative metabolism (hexose monophosphate shunt activity) and superoxide generation of neutrophils. The specificity of the suppressive effects was indicated by inhibition studies with rabbit antihuman lysozyme antibody, and with the trisaccharide of N-acetylglucosamine, a specific inhibitor of lysozyme. The results suggest that lysozyme, a product of inflammatory cells themselves, may function in a negative feedback system to modulate the inflammatory response.
Images.